Clinical trials: PET CT
Prostate Cancer, PET/CT
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent [18F]AlF-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of…
- Trial name
- NCT06756334
- Testing
- [18F]AlF-PSMA-N5, [18F]F-DCFPyL
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Paraganglioma
Exendin PET/CT for Imaging of Paragangliomas
Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets.
- Trial name
- ENTRAP (NCT05418907)
- Testing
- 68Ga-NODAGA-exendin-4 PET/CT
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Hormone Refractory Prostate Cancer
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory)…
- Trial name
- NCT00928252
- Testing
- IV fluorine-18 labeled methylcholine before PET/CT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Queen's Medical Center
Muscle-Invasive Bladder Carcinoma
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic…
- Trial name
- EFFORT-MIBC (NCT04724928)
- Testing
- Metastasis directed therapy (MDT), Immunotherapy, Standard of care
- Where
- Belgium
- Volunteers
- 156 people
- Sponsor
- University Hospital, Ghent
Prostate Cancer (Adenocarcinoma)
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of…
- Trial name
- NCT06612580
- Testing
- 68Ga-AAZTA-NI-093
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Lung Cancer
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn how accurately an endobronchial ultrasound transbronchial needle aspiration (EBUS -TBNA) may detect mediastinal lymph node metastases in patients with clinical stage I and II…
- Trial name
- NCT00832715
- Testing
- EBUS-TBNA
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Gastro-Entero-Pancreatic Tumors (GEPs)
Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors
Gastro-Entero-Pancreatic tumors (GEPs) are a subset of Neuroendocrine tumors (NETs) derived from the primitive gut and include digestive and bronchial NETs.
- Trial name
- DOTATATENET (NCT02150408)
- Testing
- PET-CT
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Non Small Cell Lung Cancer, Surgery
Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation
The recommended adjuvant therapy for stage Ⅱa-Ⅲb Non-small cell lung cancer (NSCLC) were perioperative chemotherapy. The adjuvant or neoadjuvant chemotherapy for early stage lung cancer improved about 5% 5-year survival.
- Conditions
- Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy
- Trial name
- Neoafa (NCT04470076)
- Testing
- Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin, Surgical treatment, Adjuvant treatment:afatinib
- Volunteers
- 30 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Oligometastatic Breast Carcinoma, Radiomics
FDG PET/CT Radiomics for True Oligometastatic Breast Cancer
FDG PET CT Radiomics for True Oligometastatic Breast Cancer
- Trial name
- NCT07872332
- Volunteers
- 100 people
- Sponsor
- Sohag University
Osteo Arthritis
Bone Forming at Prosthetic Surfaces. Fingerprint2
What is the intensity of F-PET uptake in healthy and osteo arthritic femur and acetabulum, compared to the uptake adjacent to four analyzed endoprosthetic components 1½ and 6 months after surgery?
- Trial name
- NCT01623687
- Testing
- Component for acetabulum (Regenerex RingLoc cup), Components for the acetabulum (Lubinus cross linked cup), Arthroplasty components are for the femur (Cemented Lubinus SP II stem)
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Uppsala University
Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study
The purpose of this study is to see how useful the information provided from Positron Emission Tomography (PET) scans can be in the actual planning and delivery of radiation treatment to patients who have head and neck cancers.
- Trial name
- NCT02678884
- Testing
- 18-F FDG
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- University Health Network, Toronto
Coronary Artery Disease, Carotid Artery Disease
Assessment Of Vascular Health After Niacin Therapy (AVANT)
This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic…
- Conditions
- Coronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease
- Trial name
- AVANT (NCT02003638)
- Testing
- Niacin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Prostate Cancer
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
The aim of this study is to assess the safety and dosimetry of imaging with [68Ga]Ga-OncoACP3 in patients with prostate cancer.
- Trial name
- SWAP (NCT07600554)
- Testing
- [68Ga]Ga-OncoACP3
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Unspecified Adult Solid Tumor, Protocol Specific
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
This partially randomized phase I trial studies the side effects and how well sequential dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor receptor (PDGFR) dual kinase inhibitor X-82 and…
- Trial name
- NCT02146222
- Testing
- VEGFR/PDGFR dual kinase inhibitor X-82, docetaxel, fluorine F 18 fluorothymidine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
Pioglitazone Decreases Visceral Fat Metabolism
Excess visceral fat is associated with chronic systemic inflammation and cardiovascular complications. Pioglitazone has been reported to variably influence visceral fat volume, but it its effect on metabolic activity of the…
- Trial name
- NCT01819402
- Testing
- Pioglitazone vs Glimepiride
- Where
- Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kurume University
PET/CT, Solid Tumors, Adult
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden.
- Conditions
- PET/CT, Solid Tumors, Adult, Solid Tumors, Advanced Solid Tumors
- Trial name
- GZMB_PET (NCT06916442)
- Testing
- PET/CT Imaging with GZMB-targeted tracer
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongnan Hospital
Cholangiocarcinoma
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
This phase II trial studies whether [18F]FTT can be used with positron emission tomography (PET)/computed tomography (CT) imaging to predict treatment response in patients scheduled to receive gemcitabine, cisplatin, and…
- Trial name
- NCT07673341
- Testing
- Computed Tomography, Fluorine F 18 Fluorthanatrace, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Fever of Unknown Origin
PLACE OF THE 18F-FDG-PET/CT IN THE DIAGNOSTIC WORKUP IN PATIENTS WITH CLASSICAL FEVER OF UNKNOWN ORIGIN (FUO)
Objective : To explore the diagnostic contribution of the 18F-FDG-PET/CT in a population of patients with classical fever of unknown origin (FUO), to precise its place in the diagnostic decision tree in a real-life setting and to…
- Trial name
- NCT04851379
- Where
- France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Montpellier
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown.
- Trial name
- NCT01269970
- Testing
- 18-FDG-PET-CT
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven